Abstract
Growth factor profiles could be influenced by the utilization of exogenous insulin. The data presented shows the relationship between pre-existing use of injectable insulin in women diagnosed with breast cancer and type 2 diabetes mellitus, the growth factor profiles at the time of breast cancer diagnosis, and subsequent cancer outcomes. A Pearson correlation analysis evaluating the relationship between growth factors stratified by of insulin use and controls is also provided.
Highlights
Dataset on growth factor levels and insulin use in patients with diabetes mellitus and incident breast cancer
The data presented shows the relationship between pre-existing use of injectable insulin in women diagnosed with breast cancer and type 2 diabetes mellitus, the growth factor profiles at the time of breast cancer diagnosis, and subsequent cancer outcomes
Tables Tumor registry query was followed by vital status ascertainment, and medical records review Luminexs-based quantitation of growth factors from plasma samples was conducted
Summary
Tables Tumor registry query was followed by vital status ascertainment, and medical records review Luminexs-based quantitation of growth factors (epidermal growth factor, fibroblast growth factor 2, vascular endothelial growth factor, hepatocyte growth factor, platelet-derived growth factor BB, and tumor growth factor-β) from plasma samples was conducted. United States, Buffalo, NY - 42° 530 50.3592′′N; 78° 520 2.658′′W This dataset represents the observed relationship between injectable insulin use, circulating growth factors at breast cancer diagnosis and outcomes. Reported data represents the observed association between use of injectable insulin preceding breast cancer and the growth factor profiles at the time of cancer diagnosis in women with diabetes mellitus (Table 1). C-peptide correlation with each of the studied growth factors is presented, details regarding its determination from plasma, association with cancer outcomes and use of injectable insulin has been previously reported by us [1]. Evaluation of growth factor profile association with injectable insulin use and BC outcomes was carried out under two protocols approved by both Roswell Park Cancer Institute (EDR154409 and NHR009010) and the State University of New York at Buffalo (PHP0840409E).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
